Who owns Krystal Biotech, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of KRYS from SEC Form 13F filings across 423 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 423 institutions disclosed 30.3M shares of Krystal Biotech, Inc. worth $11.08B — about 102.6% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
423
13F holders
$11.08B
value, 2026 filers
102.6%
of shares outstanding (30.3M sh)
97
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of KRYS's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 4.4M | $1.64B | 0.1% | 15% | +1.0% |
| 2 | BlackRock, Inc. | 4.2M | $1.55B | 0.0% | 14.2% | +6.1% |
| 3 | Avoro Capital Advisors LLC | 2.9M | $1.07B | 9.6% | 9.8% | 0.0% |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.6M | $585.3M | 0.0% | 5.3% | +8.1% |
| 5 | STATE STREET CORP | 1.4M | $502.2M | 0.0% | 4.6% | +2.8% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 1.2M | $461.1M | 0.0% | 4.2% | +6.5% |
| 7 | Soleus Capital Management, L.P. | 939,254 | $349.1M | 12.0% | 3.2% | -18.5% |
| 8 | Capital World Investors | 777,843 | $289.1M | 0.0% | 2.6% | -5.7% |
| 9 | VESTOR CAPITAL, LLC | 700,914 | $78.2M | 4.9% | 2.4% | +350357.0% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 698,993 | $259.8M | 0.0% | 2.4% | +8.5% |
| 11 | PRICE T ROWE ASSOCIATES INC /MD/ | 687,400 | $255.5M | 0.0% | 2.3% | +41.7% |
| 12 | Hood River Capital Management LLC | 663,375 | $246.6M | 1.8% | 2.2% | +7.1% |
| 13 | Redmile Group, LLC | 632,005 | $234.9M | 15.8% | 2.1% | -6.2% |
| 14 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 570,153 | $211.9M | 0.6% | 1.9% | +40.0% |
| 15 | Frazier Life Sciences Management, L.P. | 481,307 | $178.9M | 3.9% | 1.6% | 0.0% |
| 16 | DIMENSIONAL FUND ADVISORS LP | 476,038 | $176.9M | 0.0% | 1.6% | +1.5% |
| 17 | FIRST TRUST ADVISORS LP | 324,900 | $120.8M | 0.1% | 1.1% | -7.3% |
| 18 | Invesco Ltd. | 324,755 | $120.7M | 0.0% | 1.1% | +29.2% |
| 19 | GOLDMAN SACHS GROUP INC | 298,841 | $111.1M | 0.0% | 1% | +39.0% |
| 20 | NORTHERN TRUST CORP | 283,784 | $105.5M | 0.0% | 1% | +12.4% |
| 21 | FRANKLIN RESOURCES INC | 261,917 | $97.3M | 0.0% | 0.9% | +46.1% |
| 22 | NORGES BANKNEW | 259,030 | $96.3M | 0.0% | 0.9% | new |
| 23 | Jupiter Topco LLCNEW | 256,665 | $95.4M | 0.0% | 0.9% | new |
| 24 | BANK OF AMERICA CORP /DE/ | 256,431 | $95.3M | 0.0% | 0.9% | -1.6% |
| 25 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 254,828 | $94.7M | 0.0% | 0.9% | +5.3% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.